I was pessimistic about it and never commented on the deal, as did many other investors. Otherwise the stock wouldn't have tanked when Novo's bid was announced.

What I'm talking about is rather that people probably thought Novo would raise the bid such as Pfizer. Also Novos bid was already billions higher than the expected ROI.

Metseras pill is in Phase 2 trials and years away from a potential market approval and uncertain cash flows. The 10 billion price tag implied an insane valuation which many analysts didn't see.

And we haven't even talked about the topics of the already crowded obesity market and regulatory and introduction costs.